*ICLUSIG is indicated in adult patients with chronic phase, accelerated phase, or blast phase
CML who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for
whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315l mutation.
ICLUSIG is also indicated in adult patients with Ph+ ALL who are resistant to dasatinib; who are
to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have
the T315l mutation.
Abbreviations:2G, second-generation;CML, chronic myeloid leukaemia;ELN, European LeukemiaNet;OPTIC, Optimizing Ponatinib Treatment in CP-CML;PACE, Ponatinib Ph+ ALL and CML Evaluation Phase 2;Ph+ ALL, Philadelphia chromosome-positive acute lymphoblastic leukaemia;TKI, tyrosine kinase inhibitor.
References:1. Miller GD, et al. Biologics. 2014;8:243–54;2. Cortes J, Lang F. J Hematol Oncol. 2021;14:4;3. O’Hare T, et al. Cancer Cell. 2009;16:401–12;4. ICLUSIG® (ponatinib). Summary of Product Characteristics. Incyte. 2022;5. Cortes JE, et al. Blood. 2018;132:393–404;6. Jabbour E, et al. Am J Hematol. 2023;98:658–65;7. Hochhaus A, et al. Leukemia. 2020;34:966–84;8. Cortes JE, et al. Blood. 2021;138:2042–50.